Trial Profile
A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 10 Apr 2018 Results from extension phase of the study published in the Journal of the American Academy of Dermatology
- 26 Jun 2017 Status changed from active, no longer recruiting to completed.
- 24 Dec 2016 Results of an integrated analysis of UNCOVER-1, UNCOVER-2, UNCOVER-3, UNCOVER-A, UNCOVER-J and two other phase 1 and phase 2 studies published in the Journal of the American Academy of Dermatology.